Medtronic Debt to Equity Ratio 2010-2024 | MDT
Current and historical debt to equity ratio values for Medtronic (MDT) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. Medtronic debt/equity for the three months ending October 31, 2024 was 0.51.
| Medtronic Debt/Equity Ratio Historical Data | |||
|---|---|---|---|
| Date | Long Term Debt | Shareholder's Equity | Debt to Equity Ratio |
| 2024-10-31 | $41.33B | $48.72B | 0.85 |
| 2024-07-31 | $41.59B | $48.16B | 0.86 |
| 2024-04-30 | $39.56B | $50.42B | 0.79 |
| 2024-01-31 | $38.84B | $52.00B | 0.75 |
| 2023-10-31 | $38.44B | $51.65B | 0.74 |
| 2023-07-31 | $39.41B | $51.37B | 0.77 |
| 2023-04-30 | $39.28B | $51.67B | 0.76 |
| 2023-01-31 | $42.52B | $51.62B | 0.82 |
| 2022-10-31 | $41.18B | $52.06B | 0.79 |
| 2022-07-31 | $37.07B | $52.84B | 0.70 |
| 2022-04-30 | $38.26B | $52.72B | 0.73 |
| 2022-01-31 | $39.09B | $52.71B | 0.74 |
| 2021-10-31 | $39.60B | $52.16B | 0.76 |
| 2021-07-31 | $40.14B | $51.66B | 0.78 |
| 2021-04-30 | $41.48B | $51.60B | 0.80 |
| 2021-01-31 | $46.34B | $50.93B | 0.91 |
| 2020-10-31 | $45.57B | $50.32B | 0.91 |
| 2020-07-31 | $43.46B | $50.44B | 0.86 |
| 2020-04-30 | $39.82B | $50.87B | 0.78 |
| 2020-01-31 | $40.87B | $51.95B | 0.79 |
| 2019-10-31 | $40.33B | $50.72B | 0.80 |
| 2019-07-31 | $40.77B | $50.50B | 0.81 |
| 2019-04-30 | $39.48B | $50.21B | 0.79 |
| 2019-01-31 | $38.79B | $49.94B | 0.78 |
| 2018-10-31 | $38.44B | $49.71B | 0.77 |
| 2018-07-31 | $39.39B | $50.33B | 0.78 |
| 2018-04-30 | $40.57B | $50.82B | 0.80 |
| 2018-01-31 | $45.46B | $50.34B | 0.90 |
| 2017-10-31 | $42.88B | $51.58B | 0.83 |
| 2017-07-31 | $49.46B | $50.79B | 0.97 |
| 2017-04-30 | $49.53B | $50.33B | 0.98 |
| 2017-01-31 | $48.09B | $49.49B | 0.97 |
| 2016-10-31 | $48.11B | $50.29B | 0.96 |
| 2016-07-31 | $47.71B | $50.89B | 0.94 |
| 2016-04-30 | $47.58B | $52.06B | 0.91 |
| 2016-01-31 | $51.89B | $50.82B | 1.02 |
| 2015-10-31 | $52.68B | $52.27B | 1.01 |
| 2015-07-31 | $51.82B | $52.81B | 0.98 |
| 2015-04-30 | $53.46B | $53.23B | 1.00 |
| 2015-01-31 | $35.06B | $20.17B | 1.74 |
| 2014-10-31 | $19.34B | $19.44B | 1.00 |
| 2014-07-31 | $18.31B | $19.25B | 0.95 |
| 2014-04-30 | $18.50B | $19.44B | 0.95 |
| 2014-01-31 | $17.88B | $19.35B | 0.92 |
| 2013-10-31 | $17.72B | $18.74B | 0.95 |
| 2013-07-31 | $16.45B | $18.52B | 0.89 |
| 2013-04-30 | $16.23B | $18.67B | 0.87 |
| 2013-01-31 | $17.11B | $17.84B | 0.96 |
| 2012-10-31 | $16.79B | $17.18B | 0.98 |
| 2012-07-31 | $16.00B | $17.26B | 0.93 |
| 2012-04-30 | $15.71B | $17.11B | 0.92 |
| 2012-01-31 | $14.74B | $17.17B | 0.86 |
| 2011-10-31 | $15.01B | $16.74B | 0.90 |
| 2011-07-31 | $14.75B | $16.34B | 0.90 |
| 2011-04-30 | $14.71B | $15.97B | 0.92 |
| 2011-01-31 | $15.24B | $15.36B | 0.99 |
| 2010-10-31 | $14.49B | $14.83B | 0.98 |
| 2010-07-31 | $14.06B | $14.60B | 0.96 |
| 2010-04-30 | $13.46B | $14.63B | 0.92 |
| 2010-01-31 | $10.85B | $14.32B | 0.76 |
| 2009-10-31 | $10.68B | $13.61B | 0.79 |
| 2009-07-31 | $10.43B | $13.14B | 0.79 |
| 2009-04-30 | $10.41B | $13.18B | 0.79 |
| 2009-01-31 | $9.70B | $13.06B | 0.74 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $102.570B | $32.364B |
| Medtronic, Inc. acquired Ireland-based Covidien plc. The acquisition resulted in the formation of a new holding company incorporated in Ireland - Medtronic plc. The company currently generates revenues from four major segments - namely Cardiovascular Portfolio, Medical Surgical Portfolio, Neuroscience Portfolio and Diabetes. The Cardiovascular Portfolio, formerly reported as the Cardiac and Vascular Group, includes the Cardiac Rhythm & Heart Failure, Structural Heart & Aortic and Coronary & Peripheral Vascular divisions. The Medical Surgical Portfolio, formerly reported as the Minimally Invasive Therapies Group, includes the Surgical Innovations and the Respiratory, Gastrointestinal & Renal divisions. Neuroscience consists of Cranial & Spinal Technologies, Specialty The Neuroscience Portfolio, formerly reported as the Restorative Therapies Group, includes the Cranial & Spinal Technologies, Specialty Therapies, and Neuromodulation divisions. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Abbott Laboratories (ABT) | United States | $194.987B | 24.87 |
| Stryker (SYK) | United States | $136.147B | 30.68 |
| Boston Scientific (BSX) | United States | $130.670B | 37.57 |
| EssilorLuxottica (ESLOY) | France | $110.026B | 0.00 |
| Haleon (HLN) | United Kingdom | $43.909B | 28.53 |
| Lonza Group Ag (LZAGY) | Switzerland | $42.293B | 0.00 |
| GE HealthCare Technologies (GEHC) | United States | $35.376B | 18.35 |
| ResMed (RMD) | United States | $33.995B | 27.93 |
| Terumo (TRUMY) | Japan | $28.800B | 40.67 |
| Koninklijke Philips (PHG) | Netherlands | $23.527B | 18.01 |
| Zimmer Biomet Holdings (ZBH) | United States | $21.064B | 13.41 |
| Insulet (PODD) | United States | $17.996B | 71.67 |
| Baxter (BAX) | United States | $14.756B | 9.60 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $10.838B | 0.00 |
| BellRing Brands (BRBR) | United States | $10.021B | 40.32 |
| Bio-Rad Laboratories (BIO) | United States | $9.125B | 31.01 |
| Demant (WILYY) | Denmark | $7.926B | 0.00 |
| Lantheus Holdings (LNTH) | United States | $6.392B | 14.85 |
| Prestige Consumer Healthcare (PBH) | United States | $3.886B | 19.33 |
| Haemonetics (HAE) | United States | $3.862B | 18.85 |
| ICU Medical (ICUI) | United States | $3.751B | 35.71 |
| Perrigo (PRGO) | Ireland | $3.510B | 10.33 |
| Envista Holdings (NVST) | United States | $3.103B | 23.11 |
| Shandong Weigao Medical Polymer (SHWGF) | China | $3.010B | 0.00 |
| QuidelOrtho (QDEL) | United States | $2.894B | 18.63 |
| GN Store Nord (GNNDY) | Denmark | $2.864B | 18.36 |
| Neogen (NEOG) | United States | $2.605B | 30.05 |
| LeMaitre Vascular (LMAT) | United States | $2.074B | 50.41 |
| Green Thumb Industries (GTBIF) | United States | $1.630B | 28.52 |
| AtriCure (ATRC) | United States | $1.465B | 0.00 |
| InMode (INMD) | Israel | $1.444B | 8.68 |
| Maravai LifeSciences Holdings (MRVI) | United States | $1.371B | 0.00 |
| AdaptHealth (AHCO) | United States | $1.304B | 9.32 |
| BioLife Solutions (BLFS) | United States | $1.211B | 0.00 |
| Owens & Minor (OMI) | United States | $0.973B | 7.60 |
| CeriBell (CBLL) | United States | $0.958B | 0.00 |
| Curaleaf Holdings (CURLF) | Canada | $0.955B | 0.00 |
| Phibro Animal Health (PAHC) | United States | $0.883B | 15.58 |
| Evolus (EOLS) | United States | $0.688B | 0.00 |
| Omeros (OMER) | United States | $0.593B | 0.00 |
| VAREX IMAGING (VREX) | United States | $0.593B | 26.15 |
| Capricor Therapeutics (CAPR) | United States | $0.587B | 0.00 |
| Surmodics (SRDX) | United States | $0.572B | 0.00 |
| Verano Holdings (VRNOF) | United States | $0.445B | 0.00 |
| Cresco Labs (CRLBF) | United States | $0.429B | 0.00 |
| Quanterix (QTRX) | United States | $0.383B | 0.00 |
| ZimVie (ZIMV) | United States | $0.373B | 31.44 |
| Valneva SE (VALN) | France | $0.353B | 0.00 |
| Biote (BTMD) | United States | $0.313B | 6.86 |
| Viemed Healthcare (VMD) | United States | $0.312B | 29.70 |
| Canopy Growth (CGC) | Canada | $0.295B | 0.00 |
| Cerus (CERS) | United States | $0.293B | 0.00 |
| OraSure Technologies (OSUR) | United States | $0.283B | 18.95 |
| Sanara MedTech (SMTI) | United States | $0.276B | 0.00 |
| Zynex (ZYXI) | United States | $0.268B | 56.00 |
| High Tide (HITI) | Canada | $0.237B | 98.00 |
| Aurora Cannabis (ACB) | Canada | $0.225B | 0.00 |
| Utah Medical Products (UTMD) | United States | $0.211B | 14.54 |
| MacroGenics (MGNX) | United States | $0.200B | 0.00 |
| Sanuwave Health (SNWV) | United States | $0.188B | 2.64 |
| Organigram Holdings (OGI) | Canada | $0.184B | 0.00 |
| TerrAscend (TSNDF) | Canada | $0.181B | 0.00 |
| Brainsway (BWAY) | Israel | $0.169B | 89.60 |
| FitLife Brands (FTLF) | United States | $0.151B | 19.04 |
| Jin Medical (ZJYL) | China | $0.132B | 0.00 |
| TriSalus Life Sciences (TLSI) | United States | $0.110B | 0.00 |
| Quipt Home Medical (QIPT) | United States | $0.104B | 0.00 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.100B | 0.00 |
| Fonar (FONR) | United States | $0.096B | 10.79 |
| Veru (VERU) | United States | $0.092B | 0.00 |
| Exagen (XGN) | United States | $0.083B | 0.00 |
| Rockwell Medical (RMTI) | United States | $0.066B | 34.17 |
| InterCure (INCR) | Israel | $0.061B | 0.00 |
| Apyx Medical (APYX) | United States | $0.059B | 0.00 |
| Jushi Holdings (JUSHF) | United States | $0.054B | 0.00 |
| Modular Medical (MODD) | United States | $0.050B | 0.00 |
| Cytosorbents (CTSO) | United States | $0.048B | 0.00 |
| Safety Shot (SHOT) | United States | $0.042B | 0.00 |
| ImmuCell (ICCC) | United States | $0.041B | 0.00 |
| Allurion Technologies (ALUR) | United States | $0.018B | 0.00 |
| Nephros (NEPH) | United States | $0.016B | 0.00 |
| Flora Growth (FLGC) | United States | $0.015B | 0.00 |
| Innovative Eyewear (LUCY) | United States | $0.014B | 0.00 |
| Cellectar Biosciences (CLRB) | United States | $0.010B | 0.00 |
| NeuroMetrix (NURO) | United States | $0.008B | 0.00 |
| Meihua Medical Technologies (MHUA) | China | $0.008B | 0.00 |
| Trinity Biotech (TRIB) | Ireland | $0.006B | 0.00 |
| Leafly Holdings (LFLY) | United States | $0.005B | 0.00 |
| Agape ATP (ATPC) | $0.005B | 0.00 | |
| IM Cannabis (IMCC) | Canada | $0.004B | 0.00 |
| GlucoTrack (GCTK) | United States | $0.004B | 0.00 |
| Sharps Technology (STSS) | United States | $0.003B | 0.00 |
| Senestech (SNES) | United States | $0.003B | 0.00 |
| Akanda (AKAN) | United Kingdom | $0.002B | 0.00 |
| InVivo Therapeutics Holdings (NVIVQ) | United States | $0.001B | 0.00 |
| United-Guardian (UG) | United States | $0.000B | 12.82 |
| SNDL (SNDL) | Canada | $0.000B | 0.00 |